AnaptysBio Announces Positive Topline Results from Phase 3 Trial of Imsidolimab for GPP
Patients who responded to imsidolimab in GEMINI-1 and who moved into GEMINI-2 maintained clear or almost clear skin.
Patients who responded to imsidolimab in GEMINI-1 and who moved into GEMINI-2 maintained clear or almost clear skin.
Thank you for your interest in the 25th Annual Las Vegas Dermatology Seminar in Las Vegas! MedscapeLIVE! is pleased to announce the 2024 seminar, with…
Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.
Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.
Step into the ring for the inaugural KOL KNOCKOUT â„¢ in Oculoplastics! Experts Gary J. Lelli Jr, MD; Nicholas Robert Mahoney, MD; and Prem S.…
Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.
Real-time continuous glucose monitoring (rtCGM) facilitates the recognition of patient-specific trends of h yper- and hypoglycemia, allowing for individualized management and behavior modification. Data continue…
On the final day of Spring Dermatology Week 2024, Susan Taylor, MD, FAAD, discussed management approaches to melasma and pigmentary disorders during her session, “Management…
James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.
Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.
The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.